This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global ophthalmology drugs market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the ophthalmology drugs market. The secondary sources used for this study include US Food and Drug Administration (US FDA), European Medicines Agency (EMA), World Health Organization (WHO), National Center for Biotechnology Information (NCBI), White papers, Company Websites, Interviews with Experts, Annual Reports, SEC Filings, Investor Presentations, and MarketsandMarkets Analysis. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
A comprehensive primary research was undertaken following an initial assessment of the global ophthalmology drugs market landscape through secondary research. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from hospitals, long-term care facilities, and specialty centers. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both bottom-up and top-down approaches were used to estimate and validate the total size of the ophthalmology drugs market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
-
A list of the major global players operating in the ophthalmology drugs market was generated.
-
The revenues generated from their ophthalmology drug products have been determined through annual reports and secondary sources (including paid databases).
-
The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
-
All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.
Global Ophthalmology Drugs Market Size: Bottom-up and Top-down Approaches
Data Triangulation
After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Ophthalmology drugs are specifically designed to treat or prevent eye diseases and disorders. These medications target various parts of the eye, including the cornea, conjunctiva, lens, retina, and optic nerve. The market includes a range of effective therapies across different drug modalities, such as biologics and biosimilars (e.g., anti-VEGF drugs, monoclonal antibodies, oligonucleotides, and peptides), small molecules, gene therapy, and cell therapy. These treatments address various conditions, including age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, retinal vein occlusion, uveitis, and neurotrophic keratitis, among others.
Stakeholders
-
Pharmaceutical & biotechnology companies
-
Hospitals
-
Patient advocacy organizations
-
Specialty clinics
-
Long-term care facilities
-
Academic researchers and government research organizations
-
Private research institutes
-
Contract manufacturing organizations (CMOs)
-
Contract research organizations (CROs)
-
Venture capitalists
Report Objectives
-
To define, describe, and forecast the ophthalmology drugs market by molecule, modality, route of administration, indication, end user, and region
-
To provide detailed information regarding the factors influencing market growth (such as drivers, opportunities, restraints, and challenges)
-
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall ophthalmology drugs market
-
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
-
To profile the key players in the global ophthalmology drugs market as well as comprehensively analyze their core competencies and market rankings
-
To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
-
To track and analyze competitive developments, such as product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements, in the ophthalmology drugs market
Growth opportunities and latent adjacency in Ophthalmology Drugs Market